Stephanie K. Dougan

Stephanie K. Dougan

Auto-generated profile, based on publicly available information

Stephanie K. Dougan

Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2019 in Immunity
Verified
Journal Article
Closed access
MDMichael Dougan
Michael Dougan
GDGlenn Dranoff
Glenn Dranoff
SDStephanie K. Dougan
Stephanie K. Dougan

1 May 2019 in Gastroenterology
Verified
Journal Article
Closed access
PDF file
VBVinod P. Balachandran
Vinod P. Balachandran
GBGregory L. Beatty
Gregory L. Beatty
SDStephanie K. Dougan
Stephanie K. Dougan

5 July 2024 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
JDJulien Dilly
Julien Dilly
MHMegan T. Hoffman
Megan T. Hoffman
LALaleh Abbassi
Laleh Abbassi
ZLZiyue Li
Ziyue Li
FPfrancesca Paradiso
francesca Paradiso
AAAndrew J. Aguirre
Andrew J. Aguirre
KRAS inhibitors demonstrate clinical efficacy in pancreatic ductal adenocarcinoma (PDAC); however, resistance is common. Among patients with KRASG12C-mutant PDAC treated with adagrasib or sotorasib, mutations in PIK3CA and KRAS, and amplifications of KRASG12C, MYC, MET, EGFR, and CDK6 emerged at acquired resistance. In PDAC cell lines and organoid models treated with the KRASG12D inhibitor MRTX1133, epithelial-to-mesenchymal transition and PI3K-AKT-mTOR signaling associate with resistance to therapy. MRTX1133 treatment of the KrasLSL-G12D/+; Trp53LSL-R172H/+; p48-Cre (KPC) mouse model yielded deep tumor regressions, but drug resistance ultimately emerged, accompanied by amplifications of Kras, Yap1, Myc, Cdk6, and Abcb1a/b, and co-evolution of drug-resistant transcriptional programs. Moreover, in KPC and PDX models, mesenchymal and basal-like cell states displayed increased response to KRAS inhibition compared to the classical state. Combination treatment with KRASG12D inhibition and chemotherapy significantly improved tumor control in PDAC mouse models. Collectively, these data elucidate co-evolving resistance mechanisms to KRAS inhibition and support multiple combination therapy strategies. Significance: Acquired resistance may limit the impact of KRAS inhibition in patients with PDAC. Using clinical samples and multiple preclinical models, we define heterogeneous genetic and non-genetic mechanisms of resistance to KRAS inhibition that may guide combination therapy approaches to improve the efficacy and durability of these promising therapies for patients. See related commentary by Marasco and Misale, p. 2018

12 December 2024 in Cancer Cell
Verified
Journal Article
Closed access
CKCourtney T. Kureshi
Courtney T. Kureshi
SDStephanie K. Dougan
Stephanie K. Dougan

29 March 2022 in Nature Cancer
Verified
Journal Article
Closed access
PDF file
AHAbdel Nasser Hosein
Abdel Nasser Hosein
SDStephanie K. Dougan
Stephanie K. Dougan
AAAndrew J. Aguirre
Andrew J. Aguirre
AMAnirban Maitra
Anirban Maitra

29 March 2023 in Nature
Verified
Journal Article
Closed access
PDF file
MLMin-Sik Lee
Min-Sik Lee
CDCourtney Dennis
Courtney Dennis
INInsia Naqvi
Insia Naqvi
LDLucas Dailey
Lucas Dailey
ALAlireza Lorzadeh
Alireza Lorzadeh
NKNada Y. Kalaany
Nada Y. Kalaany